Disclosures. The Endocrine System. Objectives. Diabetes. The Endocrine System 4/5/17. Common Medications in Pediatric Endocrinology

Similar documents
DIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013

9/11/2012. Chapter 11. Learning Objectives. Learning Objectives. Endocrine Emergencies. Differentiate type 1 and type 2 diabetes

Rebecca Newberry APRN MS CDE

Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital

Target cells only respond to specific signals Different target cells have different kinds of receptors in their membranes or cytoplasm

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

Drugs used in Diabetes. Dr Andrew Smith

Pharmacologic Agents for Treatment of Type 2 Diabetes

Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016

CHAPTER 50 Endocrine Systems. Copyright The McGraw-Hill Companies, Inc. Permission required for reproduction or display.

Disclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2

The University of Arizona Pediatric Residency Program. Primary Goals for Rotation. Endocrinology

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

9.3 Stress Response and Blood Sugar

Insulin Prior Authorization with optional Quantity Limit Program Summary

Endocrine System. Chapter 9

NOTES 11.5: ENDOCRINE SYSTEM. Pages

Diabetes Mellitus in the Pediatric Patient

NSC 830: Drugs Affecting the Thyroid BROOKE BENTLEY, PHD, APRN

Provide preventive counseling to parents and patients with specific endocrine conditions about:

PITUITARY: JUST THE BASICS PART 2 THE PATIENT

Diabetes: We ve Come a Long Way, Baby! Amy Wachter, MD Christiana Care Endocrinology March 22, 2018

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

Objectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment

In-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University

The Endocrine System 2

Instructor s Manual Chapter 28 Endocrine Alterations. 1. Which of the following is an example of a negative feedback system?

Advanced Practice Education Associates. Endocrine

Hormones. Introduction to Endocrine Disorders. Hormone actions. Modulation of hormone levels. Modulation of hormone levels

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Laura Stewart, MD, FRCPC Clinical Associate Professor Division of Pediatric Endocrinology University of British Columbia

Diabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

Endocrinological Outcome Among Treated Craniopharyngioma Patients

Objectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17

Diabetes: Inpatient Glucose control

Managing Addison s Disease

Technology for Diabetes: 101 Basic Rules of the Road. Karen Hamon RN, BSN, CDE Stephen Stone MD, FAAP Neil H. White, MD, CDE

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Insulin Management. By Susan Henry Diabetes Specialist Nurse

Xultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow

Insulin Initiation and Intensification. Disclosure. Objectives

Mineralocorticoids: aldosterone Angiotensin II/renin regulation by sympathetic tone; High potassium will stimulate and ACTH Increase in aldosterone

OVERVIEW OF PEDIATRIC DIABETES Alan B. Cortez, M.D. Pediatric Endocrinology Chief, Department of Pediatrics Kaiser-Permanente, Orange County

Care of patients with endocrine system disorders

ADDISON S DISEASE THE FACTS YOU NEED TO KNOW

Children s Hospital & Research Center Oakland. Endocrinology

Adrenal Insufficiency in Children

Lantus levemir conversion

Endocrine part two. Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy

Patient Education Handouts Table of Contents 2013 General Diabetes Information Monitoring and Management

Diabetes in Pregnancy

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

Endocrine system overview

Endocrine secretion cells secrete substances into the extracellular fluid

Type 1 Diabetes Update Robin Goland, MD

Learning Objectives. Are you ready for more insulin formulations?

Neuroendocrine challenges following hemispherectomy

Initiating Injectable Therapy in Type 2 Diabetes

INSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min.

GLP-1 receptor agonists for type 2 diabetes currently available in the U.S.

Biology 30. Morinville Community High School. Unit 2: Endocrine System. Name:

Diabetic medications

From the editors desk

Chapter 45-Hormones and the Endocrine System. Simple Hormone Pathways

OBJECTIVES. Rebecca McEachern, MD. Puberty: Too early, Too Late or Just Right? Special Acknowledgements. Maryann Johnson M.Ed.

Why is my body not changing? Conflicts of interest. Overview 11/9/2015. None

DEMYSTIFYING INSULIN THERAPY

Diabetes Management: A diagnostic perspective

Audit of Adrenal Function Tests. Kate Davies Senior Lecturer in Children s Nursing London South Bank University London, UK

Oral and Injectable Medication Options for Diabetes Treatment

2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:

9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends

Pancreas. Endocrine pancreas - Islets of Langerhans A or alpha cells glucagon B or beta cells insulin Delta cells somatostatin

Hormonal regulation of. Physiology Department Medical School, University of Sumatera Utara

New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

Clinical Guideline. SPEG MCN Protocols Sub Group SPEG Steering Group

SHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR mg TM ) for precocious puberty

Module 5. Understanding Insulin Therapy

CHAPTER 41: Animal Hormones

BIOM2010 (till mid sem) Endocrinology. e.g. anterior pituitary gland, thyroid, adrenal. Pineal Heart GI Female

Congenital hypothyroidism and your child

I. General Considerations

Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption),

Chapter 12 Endocrine System (export).notebook. February 27, Mar 17 2:59 PM. Mar 17 3:09 PM. Mar 17 3:05 PM. Mar 17 3:03 PM.

4.04 Understand the Functions and Disorders of the ENDOCRINE SYSTEM Understand the functions and disorders of the endocrine system

Endocrine Emergencies: Recognition and Management

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

What s New in Diabetes Medications. Jena Torpin, PharmD

Running head: THE OPTIMAL TREATMENT FOR ADDISON S DISEASE

Testosterone and other male hormones seem to be related to aggressive behavior in some species

Chapter 20. Endocrine System Chemical signals coordinate body functions Chemical signals coordinate body functions. !

What s New on the Horizon: Diabetes Medication Update

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare

Hypothalamic Control of Posterior Pituitary

GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018

PROBLEMS WITH REGULATION AND METABOLISM. Objectives A & P 8/11/2011

9.2 Hormonal Regulation of Growth

Growth hormone therapy in a girl with Turner syndrome showing a large increase over the initially predicted ht of 4 5

Transcription:

Disclosures Common Medications in Pediatric Endocrinology I have nothing to disclose Carrie A. Tolman, CPNP Nationwide Children s Hospital Objectives The Endocrine System Review common endocrine disorders Discuss treatment options for common endocrine disorders in pediatrics The Endocrine System 5 Main Functions Produce hormones Regulate metabolism Maintain fluid and electrolyte balance in the blood Moderate growth and development, reproductive development Regulate the body s response to stress Diabetes Type 1 Diabetes Autoimmune condition that destroys beta cell function Become completely insulin dependent Type 2 Diabetes Inefficient use of insulin Insulin resistance Ultimately beta cell function failure 1

Diabetes Goals of Therapy Mimic physiologic insulin release Maintain normoglycemia as much as possible Prevent prolonged hyperglycemia Prevent acute hypoglycemia Hemoglobin A1C of <8%. Why Tight Control? MDI Insulin Therapy Basal Insulin Long acting insulin Usually given once daily Ideally 40-50% of daily insulin Bolus Insulin Rapid acting insulin Carb coverage at meal/snack time Requires carb counting ability Ideally given immediately BEFORE eating High blood glucose correction Bolus Calculation Basal/Bolus Therapy 2

Long-Acting Insulin Lantus/Basaglar (glargine) U-100 (100units/ml) Negligible Peak Up to 24 hour duration Levemir (detemir) Duration of action between 7.6 hrs and 24 hours Usually requires BID dosing Long-Acting Insulin Toujeo (glargine) U-300 (300 units/ml) More concentrated version of Lantus Advise patients to dial the same dose as their current dose, gives 3 times the dose in smaller quantity Approved in 18 years and older Tresiba (degludec) U100 and U200 Negligible Peak May last longer than 24 hours Makes it good for patients that may miss doses Approved in 18 years and older Rapid-Acting Insulin Humalog/Novolog Onset of action is immediate to 15 minutes Peaks at 1-2 hours Duration of Action 3-4 hours Apidra Children 4 years and older Onset of action is immediate Peaks at around 100 minutes Duration of action of 2-3 hours Methods of Delivery Vials Disposable Pens Reusable pen with disposable cartridges Insulin Pump Therapy Pump Models Continuous subcutaneous insulin infusion Decreases need for injections! Daily basal rate Bolus at meals/snacks and for corrections Meters communicate with the pump Moving closer to full closed loop system with continuous glucose monitor (CGM) 3

4/5/17 Glucagon Used in case of severe hypoglycemia Unconscious Unable to take po due to risk of choking Refusing oral treatment Acts on liver glycogen to release glucose into the blood stream Given IM <20 kg give 0.5 ml >20 kg give 1 ml May cause vomiting-roll patient to side after administration Mini-dose glucagon Type 2 Diabetes Increasing rates due to childhood obesity Limited options available in children Very few oral medications studied in pediatrics Lifestyle changes are first line treatment! Bariatric surgery is now viewed as a treatment Insulin is an option, but not usually 1st line Unfortunately, beta cell destruction is more rapid in youth than adult counterparts Type 2 Diabetes T2DM Treatments Insulin & Metformin are the only 2 FDA approved in pediatrics Biguanides: Decrease hepatic glucose output, increase hepatic & muscle sensitivity w/o direct effect on beta cell function Thiazolidenediones (TZDs): Improve peripheral insulin sensitivity Sulfonylureas: Increase insulin secretion (secretagogue) Meglitinide: Short term promotion of glucose stimulated insulin secretion Glucosidase inhibitors: slow CHO absorption Type 2 Diabetes Thyroid Due to side effects, dose should be titrated slowly. Before initiating therapy, need to assess renal and hepatic function 500 mg once daily for 2 weeks Increase in 500 mg increments every 1-2 weeks as tolerated Max daily dose 2000 mg daily XR form associated with fewer GI side effects Always take with food! Metformin is the only oral medication approved (down to age 10 years) Adequate monotherapy for about 50% of youth with T2DM Biguinide insulin sensitizer Binds in the liver to decrease hepatic glucose production Improves glucose uptake at the muscle and fat Most common side effects are GI-diarrhea, bloating, nausea Most severe side effect is lactic acidosis-rare in children and usually only in context of renal failure Converts iodine from food to T3 and T4 Controls metabolism Regulated by pituitary (TSH) through negative feedback 4

4/5/17 Hypothyroidism Congenital (CH) Found on newborn screen by TSH Indicates agenesis, dysgenesis, ectopy or non-functioning thyroid gland Autoimmune Hashimoto s thyroiditis Associated with other autoimmune conditions (diabetes, celiac) Genetic disorder Down Syndrome Turner Syndrome Panhypopituitarism Post-ablative/post-surgery Thyroid Replacement Levothyroxine (Synthroid, Levoxyl, Levothroid) For CH, need to start ASAP!! Dose at the same time of day Can be crushed and mixed in small amount of water, breastmilk, or non-soy formula Thyroid Dosing L-thyroxine Interactions TSH >10 Age appropriate dosing of levothyroxine (L-thyroxine) Age 1-3 years 4-6 mcg/kg/day Age 3-10 years 3-5 mcg/kg/day Age 1 and up 2-4 mcg/kg/day OR 100 mcg/m2/day TSH 4.5-10 (normal free T4) Mixed recommendations on treatment Consider retesting-70% retested are normal TSH <4.5 No recommendations support treatment of subclinical hypothyroid in children Foods Do not take L-thyroxine at the same time as: Soy/soybean products Espresso coffee Walnuts Grapefruit High fiber foods Cottonseed meal L-thyroxine Interactions Precocious Puberty Medications Iron supplements Calcium supplements Multivitamins SSRIs Vitamin K-Enhanced anticoagulant effect Centrally mediated-true pituitary driven puberty Pubertal development seen Before age 8 years in girls Before age 9 years in boys Concern is compromise of adult height 5

4/5/17 Precocious Puberty Depo-Lupron-PEDS Hypothalamic-Pituitary-Gonadal Axis GnRH agonist causes downregulation of gonadotropin secretion when given continuously IM injection Monthly dosing 7.5 mg, 11.25 mg, 15 mg dosing Every 3 months 11.25 mg or 30 mg dosing May see progression of puberty in the first May include vaginal bleeding in females Lasts usually a few weeks at most Most common side effects Injection site pain/swelling Headache Weight gain Supprelin-LA is a long-acting IMPLANT Also GnRH agonist Supprelin gives 65 mcg histrelin daily over a year Cortisol Deficiency Placed on the inner aspect of upper arm Outpatient procedure with local anesthesia Most common adverse events are minor Adrenal cortical hormone under the influence of ACTH from the pituitary Stress hormone Responsible for helping maintain BP, glucose levels, immune response Symptoms may be fatigue, hypoglycemia, low BP, slow to heal/recover from illness Bruising, redness, pain at insertion site May see progression of pubertal symptoms in first few weeks 6

Cortisol Deficiency Causes: Autoimmune Addison s Disease Genetic Congenital Adrenal Hyperplasia-on newborn screen Hypopituitarism Adrenal failure Steroid suppression of adrenal glands Cortisol Replacement Replace with hydrocortisone Cortef-TID dosing 10-15 mg/m 2 daily based on body surface area Prednisone or Dexamethasone-BID dosing Used only once skeletal maturation has been reached 5mg to 7.5 mg BID Stress Dose Stress Dosing-Oral Fever >101 Nausea, vomiting, diarrhea Infectious process-strep, pneumonia Prior to surgical procedure (contact Endocrinologist for instructions) Triple the oral dose until well Repeat dose x1 if emesis Stress Dose If unable to keep oral stress dose down, will need to give injectable Solu-Cortef Give in case of severe injury, unconscious Given IM Then call 911 or get to ED Patients with adrenal insufficiency should wear a MedicAlert ID Any Questions? 7